CANDEL THERAPEUTICS INC

New study shows Candel Therapeutics’ oncolytic viral therapy boosts survival for advanced NSCLC patients who failed checkpoint inhibitors, with minimal side effects.

Explore Candel Therapeutics’ breakthrough oncolytic viral immunotherapies and track its Nasdaq performance—investor insights, market cap, and clinical prospects.

Discover how Candel Therapeutics’ oncolytic viral immunotherapy aims to transform cancer treatment and the financial hurdles it faces.

Explore Candel Therapeutics’ oncolytic viral immunotherapies—late‑stage biopharma aiming to transform cancer treatment despite financial risk.

Oncolytic viral immunotherapies pioneer Candel Therapeutics pushes breakthrough cancer treatments forward, balancing growth with financial challenges.

Explore Candel Therapeutics’ promise in oncolytic viral immunotherapy—an innovative cancer treatment breakthrough, yet a high‑risk, unprofitable stock for investors.

Discover how Candel Therapeutics uses investor inducements to fuel its oncolytic viral immunotherapy research—boosting funding while advancing promising cancer treatments.

Read how Candel Therapeutics’ new ingredient partnership could boost its phase‑III antitumor drug and what it means for investors and the oncology market.

Explore Candel Therapeutics, a late‑stage biopharma innovating oncolytic viral immunotherapies for cancer, and its latest market dynamics and investor outlook.

Explore Candel Therapeutics’ latest oncolytic viral immunotherapy updates—stock insights, market valuation, and upcoming virtual R&D event details.